All numbers are taken from the “PPV‑1780072 Pre‑clinical Dossier” (internal slide deck, 2024) and should be regarded as preliminary. | Model | Dosing Regimen | Tumor Growth Inhibition (TGI) | Comments | |-------|----------------|------------------------------|----------| | Ramos (human Burkitt lymphoma) xenograft | 30 mg/kg PO, QD, 21 d | 78 % TGI vs. vehicle | Comparable to idelalisib at the same dose. | | SU‑DHL‑6 (DLBCL) xenograft | 30 mg/kg PO, BID, 14 d | 65 % TGI | Dose‑dependent effect; higher dose (60 mg/kg) achieved 90 % TGI but with mild weight loss. | | Orthotopic pancreatic cancer (KPC model) | 20 mg/kg PO, QD, 28 d | 42 % TGI | Suggests activity in PI3Kδ‑expressing stromal components. |
The provides protection through at least 2037 (20 years from earliest filing), covering both composition‑of‑matter and method‑of‑use claims. 7. Competitive Landscape (as of 2026) | Drug | Target | Clinical Status | Relation to PPV‑1780072 | |------|--------|----------------|------------------------| | Idelalisib (Zydelig) | PI3Kδ | FDA‑approved (2014) | First‑in‑class, oral, but associated with hepatotoxicity & colitis. | | Duvelisib (Copiktra) | PI3Kδ/γ | FDA‑approved (2018) | Dual inhibition; similar safety concerns. | | Umbralisib (Ukoniq) | PI3Kδ/CK1ε | Withdrawn (2022) | Safety profile led to market exit. | | Leniolisib (Joenja) | PI3Kδ | FDA‑approved (2022) – for APDS | More selective, better tolerability. | | Experimental – BMS‑986279 , Novartis‑PI3Kδ‑X | PI3Kδ | Phase I/II | Early data suggest improved selectivity and CNS penetration. | ppv-1780072
Powered by AAKAR ASSOCIATES